JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. - Wikidata - wikimedia - TriplyDB

JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.

JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q30572002

about

Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thro Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice.The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation.Advances and challenges in the management of essential thrombocythemia.Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm Is JAK2V617F finally off the hook?JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms.Perioperative blood product administration and thromboembolic events in patients with treated polycythemia vera: a case-control study.The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury.Bleeding complications after arthroscopy in a JAK2V617F-positive patient with essential thrombocythemia and acquired von Willebrand syndrome (AVWS).

P2860

Q30315531-9AA2745F-AE55-4C89-920C-AACBA0B4D0B0 Q33419130-799E5718-0A5A-4800-8CF2-169AF4986B61 Q34737531-95818050-430B-4762-A5CD-92C71371BB82 Q36261941-B7A32F35-3574-45C9-82BD-A126BFBC8FF9 Q37506624-09153631-CBEE-4B2B-A4B2-62826AC9942C Q38542093-DB2C1DA0-095D-4D4A-BE33-303FA0CE0A2D Q42189605-40E67B30-ABB4-4442-BAEB-8AF426BB1AEE Q42791781-D288255D-5CB0-4C79-877F-60AAABE12390 Q42794052-FD445FF1-46F0-40AD-B6F1-EA5D43794FAF Q47741741-FC261C5B-3994-4B8F-B8E9-3AD9890C568D Q49442070-F76F1B40-362C-4706-89C3-875E2311E16F Q52641887-21F379B5-C50C-45F7-8875-22999A87D1C8 Q54307324-AF8B9BA5-E9F4-4791-93E1-CB3983EAAB02

P2860

JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q30572002

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

JAK2V617F-positive endothelial ...... myeloproliferative neoplasms.

@ast

JAK2V617F-positive endothelial ...... myeloproliferative neoplasms.

@en

type

label

JAK2V617F-positive endothelial ...... myeloproliferative neoplasms.

@ast

JAK2V617F-positive endothelial ...... myeloproliferative neoplasms.

@en

prefLabel

JAK2V617F-positive endothelial ...... myeloproliferative neoplasms.

@ast

JAK2V617F-positive endothelial ...... myeloproliferative neoplasms.

@en

P1433

Q30572002-D171EF1D-A5DC-4EAB-BBF0-2219BD85B10E

P1476

Q30572002-CBBDBC26-C09F-4397-93A7-D04AFEFA65FE

P2093

Q30572002-16F5CFB8-A2B6-4BD0-887E-7086661D30DE

Q30572002-412056D0-5CB8-4213-9DF1-12BE72F4D2C2

Q30572002-4A49DE44-F565-462F-9627-F81F61151810

Q30572002-4E75C3FD-ACDA-4730-BBA8-6F841416CADB

Q30572002-B676C92F-77CF-4193-BEFC-6DD847FE9370

Q30572002-B902047D-D0A5-400E-882C-78F0FAB560E4

Q30572002-E0CC6607-B7A6-4374-AD79-6C287B2B0699

Q30572002-FB5C1A8E-A9C4-44B0-A1AA-4173B6CB0866

P2860

Q30572002-018C83F7-DCCB-43C0-A986-297E09A563F4

Q30572002-01C27C1B-1440-4505-B847-3D74D669911D

Q30572002-174E2FC3-4250-407B-99AE-2CAE6F271B25

Q30572002-24702D34-2C26-4231-873D-21FBCBDAB824

Q30572002-3293C326-7F82-4A5C-82B5-E749AB446F99

Q30572002-486766E7-5C15-47A7-851D-C083C32B4613

Q30572002-533E3166-2FE5-40CC-A711-F045A540F5AF

Q30572002-53F09E95-A80A-4C6C-B873-83FB56417553

Q30572002-697907ED-251C-4909-B3C3-09133ACDB21B

Q30572002-6BE917B6-A73F-4CB1-83FB-08DEA8C720D5

P304

Q30572002-30F1EA98-D42C-4246-B2C1-A46ACCA58AC4

P31

Q30572002-A397A70E-6B0C-48F0-8744-B6276C3D30E5

P356

Q30572002-3AE98408-0C96-4700-9A1E-EB3978718762

P407

Q30572002-F0AC09AB-0221-4B18-BB01-4369897BFC57

P433

Q30572002-C3276CD4-5E89-4A2D-8E33-AE7B7C0627FE

P478

Q30572002-0C97B798-3A05-4427-9B65-382014171581

P50

Q30572002-E8FC2B88-3627-43E0-8CFD-7E103618D582

P577

Q30572002-28EA3921-3FE1-496F-896B-7F5AA5555958

P698

Q30572002-17B22F71-A9FE-4076-9734-E0EDF066AE66

P921

Q30572002-EDF49F83-D53A-40E3-8072-A53B59885896

P932

Q30572002-7B986BB3-3EED-4E7B-94CD-F1BA1E6505FF

P356

PNAS.1312148111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

JAK2V617F-positive endothelial ...... n myeloproliferative neoplasms

@en

P2093

José A López

http://www.w3.org/2001/XMLSchema#string

Junmei Chen

http://www.w3.org/2001/XMLSchema#string

Kenneth Kaushansky

http://www.w3.org/2001/XMLSchema#string

Megan E Cosgrove

http://www.w3.org/2001/XMLSchema#string

Michelle E Roh

http://www.w3.org/2001/XMLSchema#string

Norma E Fox

http://www.w3.org/2001/XMLSchema#string

S Leah Etheridge

http://www.w3.org/2001/XMLSchema#string

Veena Sangkhae

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation

Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway

A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis

Endothelial cell heterogeneity

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

P304

2295-2300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1312148111

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Ian S Hitchcock

P577

2014-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24469804

http://www.w3.org/2001/XMLSchema#string

P921

P932

3926040

http://www.w3.org/2001/XMLSchema#string